Join DelveInsight Business Research LLP at the ESMO - European Society for Medical Oncology, from September 13-17, 2024 in Spain. Connect with our expert, Rajesh Sharma to get valuable insights into the latest developments in the healthcare industry and key aspects influencing business growth. Schedule a meeting to discuss your healthcare business challenges at [email protected] or visit: https://lnkd.in/giT7zdb3 #esmo #esmo2024 #esmoconference #oncology #consulting #businesssolutions #healthcare #pharmaceutical #pharma #lifesciences
DelveInsight Business Research LLP
Market Research
A premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry
About us
DelveInsight is a leading Healthcare Consulting and Market Research Firm focused exclusively on the healthcare industry. We support companies by providing end-to-end comprehensive solutions to improve their performance and in making long-lasting decisions for their businesses. We advise leading decision-makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.
- Website
-
https://www.delveinsight.com/
External link for DelveInsight Business Research LLP
- Industry
- Market Research
- Company size
- 51-200 employees
- Headquarters
- New Delhi
- Type
- Privately Held
- Founded
- 2014
- Specialties
- Industry Insight and Business Intelligence, Competitive and future landscape, Strategic input on Active Pharmaceutical Ingredient (API) market, Market Research Report, Business Consulting, Pharma Market Analytics, Disease Landscape, Biotech Consulting, Pharma Due Dilligence, Pharma Competitive Intelligence, Pharma Market Assessment, Clinical Trial Monitoring, Epidemiological Forecasts, Drug pipeline analysis, Commercial Analysis, Pricing and Reimbursement Analysis, Congress/Conference Analysis, R&D Analysis, and Healthcare Consulting
Locations
-
Primary
New Delhi
New Delhi, 110075, IN
-
304 S. Jones Blvd #2432,
Las Vegas, NV 89107, US
Employees at DelveInsight Business Research LLP
Updates
-
Med-Tech News & Trends: FDA Cleared the Omnipod® 5 Automated Insulin Delivery System for Use in People with Type 2 Diabetes Vericel® Corporation Announced the FDA Approval and Commercial Availability of MACI Arthro Research Demonstrated the Success of Systematic Ultrasound Imaging in the Management of Non-melanoma Skin Cancer Through Image-guided Superficial Radiation Therapy SDC (Statistics & Data Corporation) Capture Revolutionized Clinical Trials With its New BYOD ePRO Solution PaceMate® Acquired Medtronic Paceart Optima™ System KARL STORZ Acquired a US-headquartered company to Establish a Surgical Robotics Hub and Advance Performance-Guided Surgery Get more details, at: https://lnkd.in/gEHSNvci #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #medtech #medtechnews
Latest Med-Tech News and Updates
https://www.delveinsight.com/blog
-
DelveInsight’s hepatic tumor pipeline report highlights a dynamic field with 75+ active players developing 75+ pipeline therapies for hepatic tumor treatment. Key companies such as Can Fite BioPharma (CANFY), MiNA Therapeutics, Medivir AB, SillaJen, Akeso, Shanghai Junshi Biosciences Co Ltd, Genmab, Janssen Biotech, Inc., and others are actively working on new drugs to enhance the treatment landscape. Notable pipeline therapies include Namodenoson, MTL CEBPA, Fostroxacitabine bralpamide, ETN101, Pexastimogene devacirepvec, Cadonilimab, Toripalimab, Amivantamab, Bevacizumab biosimilar, SRF388, GNS561, and many more, each in various stages of clinical trials. Fore more information, visit: https://lnkd.in/gRSc5QFC #HepaticTumor #DrugDevelopment #ClinicalTrials #DelveInsight
Hepatic Tumor Clinical Trial Pipeline
globenewswire.com
-
According to DelveInsight’s analysis, the IDH inhibitor market is projected to grow at a significant CAGR by 2034. Leading companies such as Servier and Bayer are advancing novel IDH inhibitors, with key candidates including Vorasidenib and BAY1436032 expected to enter the market in the coming years. Get detailed insights here: https://lnkd.in/gzsHeFqM #IDHInhibitors #PharmaInnovation #DrugDevelopment #DelveInsight
IDH Inhibitor Market
globenewswire.com
-
According to DelveInsight, the global antibiotic resistance market is set to grow at a CAGR of approximately 6% by 2030. In 2023, urinary tract infections generated the highest revenue share within this market segment. Key companies in the antibiotic resistance field include Melinta Therapeutics, Basilea Pharmaceutica, Theravance Biopharma US, Inc., Wockhardt Ltd., Paratek Pharmaceuticals, Seres Therapeutics, AbbVie, Pfizer, Johnson & Johnson, Novartis, GSK, Cipla, Roche, Sanofi, Bayer, AstraZeneca, Teva Pharmaceuticals, and Viatris. For further details, visit: https://lnkd.in/gxAZXtKa #AntibioticResistance #PharmaInnovation #DrugDevelopment #DelveInsight
Global Antibiotic Resistance Market
globenewswire.com
-
According to DelveInsight’s analysis, the market size for Leigh syndrome in the 7MM is projected to grow significantly at a robust CAGR by 2034. The prevalence of Leigh syndrome is about 1 in 30,000 to 1 in 40,000 people at birth, with mitochondrial DNA-associated Leigh syndrome occurring in approximately 1 in 100,000 to 1 in 140,000 births. Leading companies like PTC Therapeutics, Inc. and Abliva AB are developing innovative therapies for Leigh syndrome, including Vatiquinone and NV354, which are expected to make a significant impact on the market. Get more detailed insights: https://lnkd.in/gJmvf23G #LeighSyndrome #RareDiseases #DrugDevelopment #DelveInsight
Leigh Syndrome Market
globenewswire.com
-
According to DelveInsight’s analysis, the GLP-1 agonists market is expected to grow at a significant CAGR by 2034. Leading companies such as Novo Nordisk, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, ECCOGENE 诚益生物, and AstraZeneca are advancing novel GLP-1 agonists, which will enter the market in the coming years. Key GLP-1 agonists include Saxenda, Enobosarm, VK2735, TERN-601, and ECC5004. Get more detailed insights: https://lnkd.in/gJxmvdcM #GLP1Agonists #PharmaInnovation #DrugDevelopment #DelveInsight
GLP-1 Agonists Market
globenewswire.com
-
According to DelveInsight, the market for cell and gene therapy in Parkinson's disease across the 7MM is projected to grow significantly at a robust CAGR by 2034. In 2023, there were about 2.6 million diagnosed cases in the 7MM, with numbers expected to increase by 2034. Leading companies advancing this field include MeiraGTx, Hope Biosciences, Sumitomo Pharma America, Inc., Prevail Therapeutics, BlueRock Therapeutics, and Voyager Therapeutics, Inc.. These firms are developing innovative cell and gene therapies poised to make a substantial impact on the market. Notable therapies under development include AAV-GAD, HB-adMSCs, CT1-DAP001/DSP-1083, PR001 (LY3884961), Bemdaneprocel (BRT-DA01), and VY-AADC. For more detailed insights, visit: https://lnkd.in/gFD7YnKE #CellAndGeneTherapy #ParkinsonsDisease #InnovativeTherapies #DelveInsight #DrugDevelopment
Cell and Gene Therapy in Parkinson's Disease Market
globenewswire.com
-
A heartfelt congratulations to Dishant Kapoor on completing two years with DelveInsight Business Research LLP! Your unwavering commitment to excellence, innovative spirit, and collaborative mindset have not only propelled your career forward but have also played a pivotal role in driving our company's mission. Here's to many more years of shared achievements and continued success! #Anniversary #DelveInsight #TeamSpirit #Milestone #EmployeeAppreciation #HardWork #Commitment #Dedication #SuccessStory #Gratitude #Celebration
-
Oncolytic virus therapies using the vaccinia virus offer a promising strategy for cancer treatment by exploiting the virus's ability to specifically infect and destroy cancer cells. Originally utilized in the smallpox vaccine, the vaccinia virus has been modified to function as an oncolytic virus due to its strong replication capacity and its ability to provoke robust immune responses. These engineered viruses can be tailored to selectively target tumor cells while sparing healthy tissues, and they can be equipped with therapeutic genes to boost their anticancer effects. The virus's replication inside tumor cells leads to their destruction, which not only directly kills the cancer cells but also activates the immune system to recognize and attack the tumor. Currently, several companies, including Genelux Corporation, SillaJen, BioInvent International AB, BioEclipse Therapeutics, Inc, Transgene, VacV Biotherapeutics, and others, are developing vaccinia virus oncolytic therapies at various stages of development. Explore the most promising vaccinia virus-based oncolytic virus therapies in the pipeline at https://lnkd.in/gFxHCwiX
7 Upcoming Vaccinia Virus-associated Oncolytic Virus Therapies
https://www.delveinsight.com/blog